The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Journal article published in 2023 by
Dirk Jochmans 
,
Cheng Liu,
Kim Donckers,
Antitsa Stoycheva,
Sandro Boland,
Sarah K. Stevens,
Chloe De Vita,
Bert Vanmechelen ,
Piet Maes ,
Bettina Trüeb,
Nadine Ebert,
Volker Thiel,
Steven De Jonghe,
Laura Vangeel,
Dorothée Bardiot
and other authors.
,
Cheng Liu,
Kim Donckers,
Antitsa Stoycheva,
Sandro Boland,
Sarah K. Stevens,
Chloe De Vita,
Bert Vanmechelen ,
Piet Maes ,
Bettina Trüeb,
Nadine Ebert,
Volker Thiel,
Steven De Jonghe,
Laura Vangeel,
Dorothée Bardiot
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Paxlovid is the first oral antiviral approved for treatment of SARS-CoV-2 infection. Antiviral treatments are often associated with the development of drug-resistant viruses.